07.19.17
Invenra has entered a collaboration with Merck to discover fully human therapeutic antibodies against an unnamed target of interest to Merck.
"We are excited to be working with this first rate team in Merck," said Roland Green, chief executive officer, Invenra. "Invenra's ability to test antibodies for a functional phenotype early in the screening process combined with Merck's established role as a leader in this field will advance the science regarding difficult to address targets. This collaboration marks a significant milestone for Invenra in its mission to advance the field of antibody discovery through its ultra-high throughput mAbSeq technology."
Invenra's proprietary platform is based on ultra-high throughput technology allowing function forward screening of full-length antibodies using Invenra's mAbSeq technology, where antibodies can be directly and quickly interrogated in a multi-plexed fashion with a diverse set of immunotypic and biologically relevant assays. The Invenra technology allows rapid identification of high affinity mAbs with broad epitope coverage while simultaneously performing direct phenotypic screening to isolate those mAbs with the most relevant biological activity. B-Body is a novel bispecific format that can also be screened in large numbers using mAbSeq for bispecific combinations with desired phenotypic characteristics.
"We are excited to be working with this first rate team in Merck," said Roland Green, chief executive officer, Invenra. "Invenra's ability to test antibodies for a functional phenotype early in the screening process combined with Merck's established role as a leader in this field will advance the science regarding difficult to address targets. This collaboration marks a significant milestone for Invenra in its mission to advance the field of antibody discovery through its ultra-high throughput mAbSeq technology."
Invenra's proprietary platform is based on ultra-high throughput technology allowing function forward screening of full-length antibodies using Invenra's mAbSeq technology, where antibodies can be directly and quickly interrogated in a multi-plexed fashion with a diverse set of immunotypic and biologically relevant assays. The Invenra technology allows rapid identification of high affinity mAbs with broad epitope coverage while simultaneously performing direct phenotypic screening to isolate those mAbs with the most relevant biological activity. B-Body is a novel bispecific format that can also be screened in large numbers using mAbSeq for bispecific combinations with desired phenotypic characteristics.